Contact Associates in Urology - Pioneers in Urology Patient Information and Forms Directions to Our Office - Associates in Urology - West Orange, New Jersey Referring Physician Information Associates in Urology - Pioneers in Urology Home Associates in Urology Pysicians and Staff Urological Clinical Conditions Robotic Urological Surgery Associates in Urology CLinical Trials
Robotic Surgery Blog

« Salvage radiation after prostate cancer surgery | Main | Prostate cancer surgery: Should we consider a more comprehensive gleason grading after surgery »

New medicine against advanced kidney cancer

FDA approves third new targeted therapy for advanced RCC - UrologyTimes

The FDA has approved the enzyme inhibitor temsirolimus (Torisel) for the treatment of advanced renal cell carcinoma.
The approval of temsirolimus follows the December 2005 approval of sorafenib (Nexavar) and the January 2006 approval of sunitinib (Sutent), which represent a new class of targeted therapies for advanced RCC.

The article in the New England Journal of Medicine showed an improvement in survival of 3 months with temsirolimus. This will be an important addition in helping patients with advanced kidney cancer.

Posted by Domenico Savatta, M.D. on June 7, 2007 6:22 PM | | | |

TrackBack

TrackBack URL for this entry:
http://www.njurology.com/blog/mt-tb.cgi/247

Post a comment

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)

Subscribe to This Blog